FDA takes second action under international collaboration, approves new treatment option for patients with chronic lymphocytic leukemia - FDA Press Releases

As part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration and Health Canada, the FDA granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma

from FDA Press Releases RSS Feed https://ift.tt/35rKLWR
via IFTTT